论文信息 - Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one, by Fragment-Based Drug Design. - 字舞流文

Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one, by Fragment-Based Drug Design.

J. Lawson | D. Balakrishna | D. Dougan | L. Madakamutil | B. Knight | M. Sabat | E. Taylor | C. Wyrick | N. Scorah | Haixia Wang | M. Hixon | D. McConn | Phong H. Vu | Christopher R. Smith | Mark Sabat | Deepika Balakrishna